Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
62 hedge funds and large institutions have $8.84M invested in Evofem Biosciences, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 17 closing their positions.
238% more call options, than puts
Call options by funds: $963K | Put options by funds: $285K
13% less funds holding
Funds holding: 71 → 62 (-9)
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
55% less capital invested
Capital invested by funds: $19.8M → $8.84M (-$10.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$490K |
| 2 |
VF
Virtu Financial
New York
|
+$130K |
| 3 |
Renaissance Technologies
New York
|
+$79.6K |
| 4 |
JP Morgan Chase
New York
|
+$73.8K |
| 5 |
MCP
Mirador Capital Partners
Pleasanton,
California
|
+$38.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$1.27M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$798K |
| 3 |
DC
Davenport & Co
Richmond,
Virginia
|
-$173K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$137K |
| 5 |
TAM
Tocqueville Asset Management
New York
|
-$112K |
EVFM Hedge Fund Activity: Q4 2021 in Review
62 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q4 2021, worth a combined $8.84M — down 55% from $19.8M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of EVFM and 8 opened new positions — a net loss of 9 holders — while 15 trimmed existing stakes and 12 added.
The largest buyer was GSA Capital Partners, adding an estimated $490K. The largest seller was D.E. Shaw & Co, cutting an estimated $1.27M.
- 62 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q4 2021, down from 71 in Q3 2021.
- Funds reported $8.84M of Evofem Biosciences, Inc. Common Stock stock for Q4 2021, down 55% quarter-over-quarter.
- 8 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q4 2021 and 17 closed out, a net change of -9 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q4 2021 was GSA Capital Partners, an estimated $490K added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q4 2021 was D.E. Shaw & Co, an estimated $1.27M sold.
Based on aggregated 13F filings for Q4 2021.